Glucocorticoid-Induced Hypogonadism
Chronic corticosteroids suppressing the gonadal axis (and bone)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA product (drug class adverse effect)
Reference only. Not medical advice.
What can go wrong
The compounding danger is to bone: glucocorticoid-induced osteoporosis plus androgen deficiency push the skeleton the same direction, while the sexual and constitutional symptoms get absorbed into 'the illness' and testosterone is never checked. Risk also lies in over-treating with hormones when the suppression would improve with steroid taper; conversely, ignoring it leaves bone and quality of life unprotected.
This is something to take to a clinician. The Atlas can tell you what is known about glucocorticoid-induced hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Chronic glucocorticoid therapy (e.g. prednisone for autoimmune, pulmonary, or transplant conditions) suppresses testosterone through multiple levels of the HPG axis - reducing hypothalamic GnRH and pituitary LH/FSH output and exerting direct inhibitory effects on the testes. The result is a predominantly central, low-gonadotropin hypogonadism that compounds the well-known glucocorticoid risks to bone (glucocorticoid-induced osteoporosis), since low testosterone also reduces bone mineral density. It is a frequently overlooked iatrogenic cause of low libido, ED, and fatigue in patients on long-term steroids.
Prednisone fixes the inflammation and quietly turns down the gonadal axis - and the bone that low testosterone was protecting.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Glucocorticoids act at several points: they suppress hypothalamic GnRH secretion and pituitary gonadotropin (LH/FSH) release, and they have direct inhibitory effects on Leydig-cell testosterone production. The net pattern is low testosterone with low or inappropriately normal gonadotropins (secondary hypogonadism). Glucocorticoids independently drive bone loss (reduced osteoblast activity, increased resorption, reduced calcium absorption), so the testosterone deficit and the steroid both push the same way on bone - a compounding risk that makes recognition matter. The suppression is generally dose- and duration-dependent and improves as steroids are tapered.
The compounding bone problem
What gets missed: the patient on long-term prednisone has two overlapping threats to the skeleton. Glucocorticoid-induced osteoporosis is one of the most common causes of secondary osteoporosis, and androgen deficiency adds a second hit to bone mineral density. Yet the sexual and constitutional symptoms (low libido, ED, fatigue, low mood) are easily folded into 'the underlying illness' or 'the steroids,' and testosterone is never measured. The principled response mirrors other iatrogenic hypogonadism: identify the pattern (low T, low/normal gonadotropins), minimize the steroid dose where the primary disease allows, ensure bone protection, and consider hormone therapy selectively rather than reflexively - because the suppression frequently improves with steroid taper.
What it does to fertility
Suppressed gonadotropins can impair spermatogenesis; effects generally improve with steroid dose reduction.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- LH and FSH
- Bone mineral density (DXA)
- Steroid dose review
What people get wrong
Often saidLow libido and ED on long-term prednisone are just part of being sick
ActuallyChronic glucocorticoids suppress the gonadal axis at multiple levels and lower testosterone. It is a recognized iatrogenic hypogonadism - and it compounds steroid-induced bone loss, so it is worth identifying.
Often saidTestosterone is the obvious fix
ActuallyThe suppression is dose-dependent and frequently improves with steroid taper. Minimizing the steroid where the disease allows, plus bone protection, addresses root cause; hormone therapy is a selective add-on, not an automatic answer.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Pattern
- Predominantly secondary - suppressed LH/FSH
- Levels affected
- Hypothalamus, pituitary, and direct testicular
- Major comorbid risk
- Glucocorticoid-induced osteoporosis, compounded by low T
- Dose dependence
- Greater with higher dose and longer duration
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Glucocorticoid-Induced Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
MacAdams et al.1986
Demonstrated that glucocorticoid administration lowers serum testosterone in men, supporting a direct suppressive effect
Glucocorticoid-induced osteoporosis guidelines (ACR)2017
Codified bone-protection strategies for chronic steroid users; relevant because low T compounds the bone risk